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Thrombopoietin (TPO), a regulatory factor in platelet production, was purified from the conditioned medium of ‘INK-01 cells cultured in the 
presence of human interleukin-1. The N-terminal sequence of purified TPO was determined to be VPPGEDSKDVAAPHRQPLT, identical to that 
of the N-terminal region of human in~rleukin-6 (IL-6). Two forms of TPO with molecular masses of 24 and 27 kDa were identified as IL-4 by 
Western analysis using an anti-IL-6 antibody. Commercial recombinant human IL-6 produced in Escherichia coli, stimulated megakaryocyte colony 
formation in the presence of mouse interleukin-3 and increased the number of peripheral platelets in mice in a dose-dependent manner. From these 
results, it is concluded that human IL6 has thrombopoietic activity. 
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1. INTRODUCTION 
Thrombopoietin (TPO) has been thought to be a 
humoral regulatory factor in thrombopoiesis. The 
molecular nature of TPO has not yet been clarified, 
although several attempts at purification have been 
reported [1,2]. We established a cell line, TNK-01, 
derived from liposarcoma tissue of a patient who had 
shown a marked thrombocytosis and 
me~akaryoc~osis. After removal of the tumor, the 
platelet count returned to normal, indicating secondary 
thrombocytosis due to liposarcoma. We found the 
thrombopoietic activity in vivo and in vitro in the con- 
ditioned medium of TNK-01 cells cultured in the 
presence of human interleukin-1. In this paper, we 
describe some physicoche~c~ properties of the 
purified TPO, human interleukind (IL-6), and its 
thrombopoietic activity. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
The cell line TNK-01 established from the tumor was maintained 
in Dulbecco’s modified Eagle medium (DMEM, Gibco Laboratories) 
containing 10% fetal calf serum (FCS, Hyclone Laboratories) and 
antibiotics at 37°C in humidified 5% CO2 atmosphere. TNK-01 cells 
were cultured in DMEM containing 2% FCS, antibiotics and 10 
units/ml of interleukin-I (IL-i, Boehringer Mannheim} for 4-7 days 
to obtain the conditioned medium. 
2.2. Bioassay for TPO 
Female BDFi mice (5-8 weeks old) were subcutaneously injected 
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with 0.5-l ml of samples or the vehicle for five days. Blood samples 
were taken from the vena cava inferior under anesthesia on day 5, 
and platelets were counted in a Micro Cell Counter (CC-I80, Toa 
Medical Electronics). 
The megakaryocyte colony stimuIating activity of samples was 
determined using mouse bone marrow cells by the method of 
Sakaguchi et al. [3] in the presence or absence of 100 units/ml of 
mouse interleukin-3 (IL-3). 
2.3. Purification of TPO 
Conditioned medium (3 1) was concentrated to 120 ml by 
uitrafiltration, and the concentrate was applied to a column (5.0 x 
38 cm) of DEAE-Sepharose Cl-6B equilibrated with 20 mM Tris-HCI 
buffer, pH 7.4, containing 0.1 M NaCl. The column was washed with 
the same buffer, and the concentrated pass-through fraction was sub- 
jected to TSK G3OOOSW (2.5 x 60 cm) gel-permeation HPLC. Frac- 
tions containing TPO were pooled, concentrated, and subjected to a 
reverse phase column (Vydac Protein C4,4.6 x 250 mm) equilibrated 
with 5% acetonitriIe in 0.1% trifluoro~etic acid (TFA). The proteins 
absorbed were eluted with a linear gradient of acetonitrile from 5% 
to 80% in 0.1% TFA. Pooled TPO fractions were then subjected to 
a second reverse phase HPLC in the same manner as described above 
to obtain 20 pg of purified TPO. 
2.4. Amino acid se4uence analysis 
The amino acid sequence analysis was carried out using an Applied 
Biosystems 470A protein sequencer equipped with a model 120A on- 
line PTH-analyzer. 
2.5. Electrophoresis 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was carried 
out by the method of Laemmli [4] on 13.5% gels. 
3. RESULTS AND DISCUSSION 
Cytochemical and electron microscopic studies of 
TNK-01 cells showed an accumulation of lipid droplets 
in the cytoplasm. The cell markers of TNK-01 were 
determined immunohistochemic~ly using monoclon~ 
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Fig. 1. Thrombopoietic activity of the TNK-01-conditioned medium. 
Female BDFl mice (5-8 weeks old, n = 4) were subcutaneously 
injected with 1 ml of a TNK-01-conditioned medium or vehicle for 
five days. Blood samples were taken from the vena cava inferior 
under anesthesia on days 0, 1, 3, 5, 7 and 10, and platelets were 
counted in a Micro Cell Counter (CC-180, Toa Medical Electronics). 
(0) Conditioned medium of TNK-01 cultured in the presence of 10 
units/ml of human IL-la; (A) medium containing 10 units/ml of 
human IL-la; (0) medium alone. 
antibodies, and were consistent with those of the 
original tumor. The thrombopoietic activity in the con- 
ditioned medium of TNK-01 cells cultured in the 
presence of IL-l is shown in fig.1. IL-l did not show 
the activity, and the number of erythrocytes and 
leukocytes was not changed during the examination. 
Purified TPO showed a major protein band of an 
estimated molecular mass of 24 kDa and a minor band 
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Fig.2. SDS-PAGE analysis of the purified TPO. (A) Molecular mass 
estimation of the purified TPO. Marker proteins (Bio-Rad) and 
0.5 pg of the TPO were electrophoresed and stained with Coomassie 
brilliant blue R-250. (B) Western analysis. Recombinant human IL-6 
(Amersham International, lanes 1 and 5), 150 ng, non-treated TPO 
(lane 2), 200 ng, N-glycanase-treated TPO (lane 3). 200 ng and 
neuraminidase and O-glycanase-treated TPO (lane 4), 200 ng, were 
electrophoresed and subjected to Western analysis using an anti-IL-6 
antibody @enzyme). 
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Fig.3. Thrombopoietic activity of human IL-6 in vivo. 
Thrombopoietic activity of recombinant human IL-6 and the TPO 
purified from the TNK-Ol-conditioned medium were compared by 
the method described in the legend of fig. 1. Mice were injected with 
0.5 ml of samples diluted with DMEM supplemented with 2% FCS, 
and the blood samples were taken on day 5. (0) Recombinant 
human IL-6; (0) TPO purified from TNK-01-conditioned medium. 
of 27 kDa on SDS-PAGE as shown in fig.2A. The N- 
terminal amino acid sequence of purified TPO was 
identical to that of the N-terminal region of human 
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Fig.4. Megakaryocyte colony-stimulating activity of human IL-6. 
Bone marrow cells obtained from female BDFl mice were cultured 
in the presence (solid line) or absence (broken line) of 100 units/ml 
of mouse IL-3 for 6 days at 37°C in humidified 5% CO2 atmosphere. 
Cultures were mounted on glass slides, fixed with 5% glutaraldehyde 
and stained for acetylcholinesterase. A megakaryocyte colony was 
counted as a cluster of three or more acetylcholinesterase-positive 
cells. (0) Recombinant human IL-6; (0) TPO purified from a 
TNK-01-conditioned medium. 
177 
Volume 260, number 2 FEBS LETTERS January 1990 
IL-6 [5,6]. The amino acid composition of TPO was in 
accordance with that previously reported, except for 
proline (data not shown) [7]. The two forms of TPO 
were also identified as IL-6 by Western analysis using 
an anti-IL-6 antibody (fig.2B, lane 2). The 27 kDa 
form was converted to the 24 kDa form by N-glycanase 
digestion (fig.2B, lane 3), indicating that the former 
carries an N-linked carbohydrate chain. The 24 kDa 
form may contain a different type of the O-linked car- 
bohydrate chain which Gross et al. have reported [8], 
because no molecular mass change was observed by 
successive digestion of the TPO with neuraminidase 
and 0-glycanase (fig.2B, lane 4). Further evidence that 
IL-l stimulated TNK-01 cells produce IL-6 was obtain- 
ed by Northern analysis (data not shown). 
Fig.3 shows that the purified TPO and human IL-6 
produced in Escherichia coli increased the number of 
peripheral platelets in mice. Both TPO and IL-6 
stimulated the megakaryocyte colony formation in 
vitro in the presence of mouse IL-3 in a dose-dependent 
manner (fig.4). IL-6 is a muItifunctiona1 cytokine 
known to be a B cell-stimulating factor 191, a 
hybridoma-plasmacytoma growth factor [lo], a 
hepatocyte-stimulating factor 1 [l l] and an interferon- 
& [ 121. In the hemopoietic system, Ikebuchi et al. [I 31 
have reported that IL-6 stimulated the blast colony for- 
mation with IL-3 synergistically in cultured bone mar- 
row cells. Recently, Ishibashi et al. have reported that 
human IL-6 is a promotor of the maturation of murine 
megakaryocytes [14]. In addition to these reports, the 
results shown in this paper reveal that IL-6 acts as a 
regulator of thrombopoiesis in vivo. 
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